TY - JOUR
T1 - Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failure
AU - Schierwagen, Robert
AU - Gu, Wenyi
AU - Brieger, Angela
AU - Brüne, Bernhard
AU - Ciesek, Sandra
AU - Đikić, Ivan
AU - Dimmeler, Stefanie
AU - Geisslinger, Gerd
AU - Greten, Florian R.
AU - Hermann, Eva
AU - Hildt, Eberhard
AU - Kempf, Volkhard A.J.
AU - Klein, Sabine
AU - Koch, Ina
AU - Mühl, Heiko
AU - Müller, Volker
AU - Peiffer, Kai Henrik
AU - Kestner, Roxane Isabelle
AU - Piiper, Albrecht
AU - Rohde, Gernot
AU - Scholich, Klaus
AU - Schulz, Marcel H.
AU - Storf, Holger
AU - Toptan, Tuna
AU - Vasa-Nicotera, Mariuca
AU - Vehreschild, Maria J.G.T.
AU - Weigert, Andreas
AU - Wild, Peter J.
AU - Zeuzem, Stefan
AU - Engelmann, Cornelius
AU - ACLF-I Investigators,
AU - Schaefer, Liliana
AU - Welsch, Christoph
AU - Trebicka, Jonel
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Liver cirrhosis is the end stage of all chronic liver diseases and contributes significantly to overall mortality of 2% globally. The age-standardized mortality from liver cirrhosis in Europe is between 10 and 20% and can be explained by not only the development of liver cancer but also the acute deterioration in the patient's overall condition. The development of complications including accumulation of fluid in the abdomen (ascites), bleeding in the gastrointestinal tract (variceal bleeding), bacterial infections, or a decrease in brain function (hepatic encephalopathy) define an acute decompensation that requires therapy and often leads to acute-on-chronic liver failure (ACLF) by different precipitating events. However, due to its complexity and organ-spanning nature, the pathogenesis of ACLF is poorly understood, and the common underlying mechanisms leading to the development of organ dysfunction or failure in ACLF are still elusive. Apart from general intensive care interventions, there are no specific therapy options for ACLF. Liver transplantation is often not possible in these patients due to contraindications and a lack of prioritization. In this review, we describe the framework of the ACLF-I project consortium funded by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) based on existing findings and will provide answers to these open questions.
AB - Liver cirrhosis is the end stage of all chronic liver diseases and contributes significantly to overall mortality of 2% globally. The age-standardized mortality from liver cirrhosis in Europe is between 10 and 20% and can be explained by not only the development of liver cancer but also the acute deterioration in the patient's overall condition. The development of complications including accumulation of fluid in the abdomen (ascites), bleeding in the gastrointestinal tract (variceal bleeding), bacterial infections, or a decrease in brain function (hepatic encephalopathy) define an acute decompensation that requires therapy and often leads to acute-on-chronic liver failure (ACLF) by different precipitating events. However, due to its complexity and organ-spanning nature, the pathogenesis of ACLF is poorly understood, and the common underlying mechanisms leading to the development of organ dysfunction or failure in ACLF are still elusive. Apart from general intensive care interventions, there are no specific therapy options for ACLF. Liver transplantation is often not possible in these patients due to contraindications and a lack of prioritization. In this review, we describe the framework of the ACLF-I project consortium funded by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) based on existing findings and will provide answers to these open questions.
KW - decompensated cirrhosis
KW - organ failure
KW - systemic inflammation
KW - systems medicine
KW - translational hepatology
U2 - 10.1152/ajpcell.00101.2023
DO - 10.1152/ajpcell.00101.2023
M3 - Journal article
C2 - 37273239
AN - SCOPUS:85164209795
SN - 0363-6143
VL - 325
SP - C129-C140
JO - American Journal of Physiology: Cell Physiology
JF - American Journal of Physiology: Cell Physiology
IS - 1
ER -